Didn't see this till now but done
Didn't see this till now but done
In its approval letter to BioNTech, the FDA mandated Pfizer to submit several study results evaluating the occurrence of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart’s surrounding membrane) following administration of the vaccine.
The final results of a study “entitled “A Non-Interventional Post-Approval Safety Study of the Pfizer-BioNTech COVID-19 mRNA Vaccine in the United States,” to evaluate the occurrence of myocarditis and pericarditis following administration of COMIRNATY is due October 31, 2025.
The final results of another study evaluating the occurrence of myocarditis and pericarditis following administration of the vaccine is due on September 30, 2024.
>
In its approval letter to BioNTech, the FDA mandated Pfizer to submit several study results evaluating the occurrence of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart’s surrounding membrane) following administration of the vaccine.
>
The final results of a study “entitled “A Non-Interventional Post-Approval Safety Study of the Pfizer-BioNTech COVID-19 mRNA Vaccine in the United States,” to evaluate the occurrence of myocarditis and pericarditis following administration of COMIRNATY is due October 31, 2025.
>
The final results of another study evaluating the occurrence of myocarditis and pericarditis following administration of the vaccine is due on September 30, 2024.
(post is archived)